{
  "id": 4736125,
  "title": "Maze Therapeutics CSBO Dandekar divests $206,823 of common stock",
  "url": "https://urgent.news/2026/08/31/maze-therapeutics-csbo-dandekar-divests-206-823-of-common-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-31T23:01:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/maze-therapeutics-csbo-dandekar-divests-206823-of-common-stock-93CH-4883362"
  },
  "original_language": "en",
  "account": "Maze Therapeutics' Chief Strategy and Business Officer, Atul Dandekar, sold 7,500 shares of the company's common stock on August 28, 2026, for a total of $206,823. The sale was made under a pre-arranged Rule 10b5-1 trading plan, with shares traded at a weighted average price of $27.5765, varying between $27.31 and $28.01 per share. The sale follows a year-long performance where the stock offered an 83% return, despite dropping 36% year-to-date from a 52-week high of $53.65. InvestingPro suggests the stock is overvalued at present levels. Prior to the sale, Dandekar bought the same number of shares by exercising stock options priced at $10.42 each, amounting to $78,150, which were fully vested as of March 17, 2025. This purchase was also under the Rule 10b5-1 trading plan, initiated on September 29, 2025. Post these transactions, Dandekar owns 26,250 shares of Maze Therapeutics and additionally holds 14,143 derivative securities, specifically stock options.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "H.C. Wainwright reiterates Gain Therapeutics stock rating at buy",
        "url": "https://urgent.news/2026/08/31/h-c-wainwright-reiterates-gain-therapeutics-stock-rating-at-buy",
        "published": "2026-08-31T11:42:44.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}